Benoit Souchet

Benoit Souchet

Auto-generated profile, based on publicly available information

Benoit Souchet

INSERM UMR1169, 92265, Fontenay-aux-Roses, France

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in Neurobiology of Disease
Verified
Journal Article
Closed access
FGFayçal Guedj
Fayçal Guedj
PPPatricia Lopes Pereira
Patricia Lopes Pereira
SNSonia Najas
Sonia Najas
MBMaria-Jose Barallobre
Maria-Jose Barallobre
CCCaroline Chabert
Caroline Chabert
JDJean M. Delabar
Jean M. Delabar

20 December 2016 in Brain
Verified
Journal Article
Open access
PDF file
SASandro Paiva Fernandes Alves
Sandro Paiva Fernandes Alves
GCGuillaume Churlaud
Guillaume Churlaud
MAMickael Audrain
Mickael Audrain
KMKristin Michaelsen-Preusse
Kristin Michaelsen-Preusse
RFRomain Fol
Romain Fol
NCNathalie Cartier
Nathalie Cartier
Interleukin-2 (IL-2)-deficient mice have cytoarchitectural hippocampal modifications and impaired learning and memory ability reminiscent of Alzheimer’s disease. IL-2 stimulates regulatory T cells whose role is to control inflammation. As neuroinflammation contributes to neurodegeneration, we investigated IL-2 in Alzheimer’s disease. Therefore, we investigated IL-2 levels in hippocampal biopsies of patients with Alzheimer’s disease relative to age-matched control individuals. We then treated APP/PS1ΔE9 mice having established Alzheimer’s disease with IL-2 for 5 months using single administration of an AAV-IL-2 vector. We first found decreased IL-2 levels in hippocampal biopsies of patients with Alzheimer’s disease. In mice, IL-2-induced systemic and brain regulatory T cells expansion and activation. In the hippocampus, IL-2 induced astrocytic activation and recruitment of astrocytes around amyloid plaques, decreased amyloid-β42/40 ratio and amyloid plaque load, improved synaptic plasticity and significantly rescued spine density. Of note, this tissue remodelling was associated with recovery of memory deficits, as assessed in the Morris water maze task. Altogether, our data strongly suggest that IL-2 can alleviate Alzheimer’s disease hallmarks in APP/PS1ΔE9 mice with established pathology. Therefore, this should prompt the investigation of low-dose IL-2 in Alzheimer’s disease and other neuroinflammatory/neurodegenerative disorders.

1 September 2014 in Neurobiology of Disease
Verified
Journal Article
Closed access
BSBenoit Souchet
Benoit Souchet
FGFayçal Guedj
Fayçal Guedj
ISIgnasi Sahún
Ignasi Sahún
ADArnaud DUCHON
Arnaud DUCHON
FDFabrice Daubigney
Fabrice Daubigney
JDJean Maurice Delabar
Jean Maurice Delabar

22 January 2014 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
ATAurore Thomazeau
Aurore Thomazeau
OLOlivier Lassalle
Olivier Lassalle
JIJillian Iafrati
Jillian Iafrati
BSBenoit Souchet
Benoit Souchet
FGFayçal Guedj
Fayçal Guedj
OMOlivier Jacques José Manzoni
Olivier Jacques José Manzoni
The geneDyrk1ais the mammalian ortholog of Drosophilaminibrain. Dyrk1alocalizes in the Down syndrome (DS) critical region of chromosome 21q22.2 and is a major candidate for the behavioral and neuronal abnormalities associated with DS. PFC malfunctions are a common denominator in several neuropsychiatric diseases, including DS, but the contribution of DYRK1A in PFC dysfunctions, in particular the synaptic basis for impairments of executive functions reported in DS patients, remains obscure. We quantified synaptic plasticity, biochemical synaptic markers, and dendritic morphology of deep layer pyramidal PFC neurons in adult mBACtgDyrk1a transgenic mice that overexpressDyrk1aunder the control of its own regulatory sequences. We found that overexpression of Dyrk1a largely increased the number of spines on oblique dendrites of pyramidal neurons, as evidenced by augmented spine density, higher PSD95 protein levels, and larger miniature EPSCs. The dendritic alterations were associated with anomalous NMDAR-mediated long-term potentiation and accompanied by a marked reduction in the pCaMKII/CaMKII ratio in mBACtgDyrk1a mice. Retrograde endocannabinoid-mediated long-term depression (eCB-LTD) was ablated in mBACtgDyrk1a mice. Administration of green tea extracts containing epigallocatechin 3-gallate, a potent DYRK1A inhibitor, to adult mBACtgDyrk1a mice normalized long-term potentiation and spine anomalies but not eCB-LTD. However, inhibition of the eCB deactivating enzyme monoacylglycerol lipase normalized eCB-LTD in mBACtgDyrk1a mice. These data shed light on previously undisclosed participation of DYRK1A in adult PFC dendritic structures and synaptic plasticity. Furthermore, they suggest its involvement in DS-related endophenotypes and identify new potential therapeutic strategies.

20 October 2015 in Frontiers in Behavioral Neuroscience
Verified
Journal Article
Open access
BSBenoit Souchet
Benoit Souchet
FGFayçal Guedj
Fayçal Guedj
ZPZsuza Penke-Verdier
Zsuza Penke-Verdier
FDFabrice Daubigney
Fabrice Daubigney
ADArnaud DUCHON
Arnaud DUCHON
JDJean M. Delabar
Jean M. Delabar
Cognitive impairment in Down syndrome (DS) has been linked to increased synaptic inhibition. The underlying mechanisms remain unknown, but memory deficits are rescued in DS mouse models by drugs targeting GABA receptors. Similarly, administration of epigallocatechin gallate (EGCG)-containing extracts rescues cognitive phenotypes in Ts65Dn mice, potentially through GABA pathway. Some developmental and cognitive alterations have been traced to increased expression of the serine-threonine kinase DYRK1A on Hsa21. To better understand excitation/inhibition balance in DS, we investigated the consequences of long-term (1-month) treatment with EGCG-containing extracts in adult mBACtgDyrk1a mice that overexpress Dyrk1a. Administration of POL60 rescued components of GABAergic and glutamatergic pathways in cortex and hippocampus but not cerebellum. An intermediate dose (60 mg/kg) of decaffeinated green tea extract (MGTE) acted on components of both GABAergic and glutamatergic pathways and rescued behavioral deficits as demonstrated on the alternating paradigm, but did not rescue protein level of GABA-synthesizing GAD67. These results indicate that excessive synaptic inhibition in people with DS may be attributable, in large part, to increased DYRK1A dosage. Thus, controlling the level of active DYRK1A is a clear issue for DS therapy. This study also defines a panel of synaptic markers for further characterization of DS treatments in murine models.

8 March 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BSBenoit Souchet
Benoit Souchet
ADArnaud DUCHON
Arnaud DUCHON
YGYuchen Gu
Yuchen Gu
JDJulien Dairou
Julien Dairou
CCClaire Chevalier
Claire Chevalier
JDJean Maurice Delabar
Jean Maurice Delabar
Down syndrome is a common genetic disorder caused by trisomy of chromosome 21. Brain development in affected foetuses might be improved through prenatal treatment. One potential target is DYRK1A, a multifunctional kinase encoded by chromosome 21 that, when overexpressed, alters neuronal excitation–inhibition balance and increases GAD67 interneuron density. We used a green tea extract enriched in EGCG to inhibit DYRK1A function only during gestation of transgenic mice overexpressing Dyrk1a (mBACtgDyrk1a). Adult mice treated prenatally displayed reduced levels of inhibitory markers, restored VGAT1/VGLUT1 balance, and rescued density of GAD67 interneurons. Similar results for gabaergic and glutamatergic markers and interneuron density were obtained in Dp(16)1Yey mice, trisomic for 140 chromosome 21 orthologs; thus, prenatal EGCG exhibits efficacy in a more complex DS model. Finally, cognitive and behaviour testing showed that adult Dp(16)1Yey mice treated prenatally had improved novel object recognition memory but do not show improvement with Y maze paradigm. These findings provide empirical support for a prenatal intervention that targets specific neural circuitries.